A

Amylyx Pharmaceuticals

Biopharmaceutical company developing neurodegenerative therapies

Vice President - Legal Operations

Full-Time
$321k - $361k
Expert
JD
Cambridge, MA, USA
RemoteMust reside in an eligible state and travel to Cambridge several times a year and to other company events as requested.
LegalLegal Counsel & Legal Support

About the job

Requirements
  • A Juris Doctor (JD) from an accredited law school and active bar membership in good standing.
  • At least 12 years of relevant healthcare compliance experience in the biotechnology, pharmaceutical, medical device, and/or life sciences industry, including demonstrated legal operations experience and experience designing, implementing, and/or enhancing organizational contracting processes.
  • Experience operating in a dynamic, small but fast-growing biotechnology environment and a proven track record in effecting organizational change.
  • Experience structuring, drafting, and negotiating licensing, mergers and acquisitions, and other complex strategic transactions.
  • Ability to manage multiple priorities simultaneously and drive execution.
  • Ability to work effectively across functions and at all levels in the organization and with external parties.
  • Strong oral and written communication and presentation skills.
  • Direct leadership and team management experience, including the ability to organize, manage, develop, and lead legal teams in a dynamic environment.
Responsibilities
  • Lead and oversee the company's contracting function, including developing scalable contracting processes, templates, policies, and governance frameworks to improve efficiency and manage risk.
  • Serve as the lead legal advisor for strategic transactions, including structuring and negotiating transactions, leading due diligence to assess risk and mitigation strategies, and supporting post-transaction integration efforts.
  • Develop a vision for a best-in-class, future-fit legal and compliance function that appropriately leverages technology, including artificial intelligence.
  • Establish legal operations best practices across the Legal and Compliance department, including matter management, budgeting, systems and technology use, and outside counsel oversight.
  • Partner with executive leadership to support organizational growth, transformation initiatives, and strategic business changes, including driving stakeholder alignment and change adoption across multiple functions.
  • Build and maintain strong relationships across the organization as a trusted advisor and collaborative business partner, and interact with the Board of Directors to provide periodic updates on strategic matters.
  • Help build and mentor a high-performing team and foster a culture of collaboration, accountability, and continuous improvement.
  • Engage as a member of the Legal and Compliance leadership team to steer the department and ensure efficient, risk-based, fit-for-purpose, business-oriented support for all organizational functions.
Desired Qualifications
  • Experience preparing and reviewing SEC filings and complying with SEC requirements.
  • Experience supporting capital markets transactions, including equity offerings.
  • Knowledge of Internal Audit in connection with SOX compliance matters.

About the company

A

Amylyx Pharmaceuticals

View
cbWebsite

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2013

Get referred to Amylyx Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 18, 2026 LUCIDITY data showed a 55% hypoglycemia-event reduction.
  • Amylyx raised $500 million in August 2026 to fund avexitide commercialization.
  • Management plans an FDA NDA filing by year-end 2026 and a 2027 launch.

What critics are saying

  • Avexitide failure leaves Amylyx without an approved product and crushes valuation.
  • The 2024 Relyvrio withdrawal damaged credibility with regulators, physicians, and investors.
  • A 2026 securities settlement for Relyvrio misstatements keeps litigation scars visible.

What makes Amylyx Pharmaceuticals unique

  • Amylyx owns avexitide, a first-in-class GLP-1 antagonist for PBH.
  • The FDA granted avexitide Breakthrough Therapy and Orphan Drug designations by 2026.
  • Amylyx still retains ALS and rare-disease expertise after Relyvrio’s 2024 withdrawal.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-13%
MarketBeat
Sep 14th, 2026
Insider selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO sells $349,811.60 in stock.

Insider selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO sells $349,811.60 in stock. September 14, 2026 Key points. * Amylyx CFO James Frates sold 10,810 shares for approximately $349,812 at an average price of $32.36. The sale covered tax withholding obligations, reducing his holdings by 4.42% to 233,625 shares. * Amylyx shares rose 6.4% to $33.64, with a market capitalization of roughly $3.75 billion. The stock has traded between $10.83 and $41.14 over the past year. * Analysts maintain a generally positive view, with a consensus "Buy" rating and an average price target of $36.50, although the company recently missed quarterly EPS estimates and is expected to post a loss for the year. * Interested in Amylyx Pharmaceuticals? Here are five stocks we like better. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James Frates sold 10,810 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.36, for a total value of $349,811.60. Following the transaction, the chief financial officer owned 233,625 shares of the company's stock, valued at $7,560,105. The trade was a 4.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Amylyx Pharmaceuticals stock up 6.4%. Shares of NASDAQ AMLX traded up $2.02 during trading on Monday, reaching $33.64. The company had a trading volume of 1,816,910 shares, compared to its average volume of 1,682,389. Amylyx Pharmaceuticals, Inc. has a 12-month low of $10.83 and a 12-month high of $41.14. The stock has a market cap of $3.75 billion, a PE ratio of -23.52 and a beta of -0.13. The business's 50-day moving average is $25.69 and its 200 day moving average is $18.87. Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year. Analyst upgrades and downgrades. A number of research firms have recently commented on AMLX. Guggenheim increased their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a "buy" rating in a report on Thursday, August 27th. Mizuho boosted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Citigroup upped their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Wolfe Research upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $36.50. Institutional trading of Amylyx Pharmaceuticals. A number of institutional investors have recently made changes to their positions in the stock. KBC Group NV purchased a new position in shares of Amylyx Pharmaceuticals during the first quarter valued at approximately $26,000. State of Wyoming purchased a new stake in Amylyx Pharmaceuticals in the second quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd grew its position in Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company's stock worth $47,000 after purchasing an additional 3,493 shares during the period. ACT Capital Management LLC bought a new stake in Amylyx Pharmaceuticals in the 4th quarter worth approximately $109,000. Finally, Seven Fleet Capital Management LP purchased a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $140,000. Hedge funds and other institutional investors own 95.84% of the company's stock. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Amylyx Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list. While Amylyx Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public. Continue following MarketBeat

Market Wire News
Sep 8th, 2026
Amylyx Pharmaceuticals to present at the 24th Annual Morgan Stanley Global Healthcare Conference.

Amylyx Pharmaceuticals to present at the 24th Annual Morgan Stanley Global Healthcare Conference. MWN-AI** Summary. Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is set to present at the 24th Annual Morgan Stanley Global Healthcare Conference, scheduled for September 15, 2026, at 12:20 p.m. ET. The presentation will be delivered via a fireside chat format, and interested parties can access a live webcast on the company's Investor Relations website. Following the event, a replay of the presentation will be available for 90 days. Amylyx Pharmaceuticals is dedicated to revolutionizing the treatment landscape for diseases with significant unmet medical needs. The company thrives on tackling challenges in healthcare with a sense of urgency and a commitment to rigorous scientific inquiry. Their current focus includes developing investigational therapies for several endocrine conditions and neurodegenerative diseases, with the goal of maximizing their potential impact on patients. Founded on the principle of innovation and addressing high unmet needs, Amylyx seeks to make meaningful advancements in the pharmaceutical sector. The company's portfolio reflects its commitment to pushing boundaries in medical science, aspiring to fulfill the needs of communities often overlooked in treatment development. For ongoing updates and further information about their research endeavors, Amylyx encourages interested stakeholders to visit their official website or follow them on platforms such as LinkedIn and X. Investors can also find specific resources on the dedicated investor section of their website. As a part of its communication strategy, Amylyx emphasizes transparency through its media and investor relations contacts, ensuring a streamlined flow of information to its stakeholders. The upcoming presentation at the Morgan Stanley conference marks another opportunity for Amylyx to share insights on its innovative work and future directions in healthcare. MWN-AI** Analysis. Amylyx Pharmaceuticals (NASDAQ: AMLX) is strategically positioning itself by participating in the upcoming 24th Annual Morgan Stanley Global Healthcare Conference. This is an important opportunity for the company to engage with investors and peers in the biotech sector, highlighting its innovative approach to treating diseases with significant unmet needs. As a financial analyst, there are several key factors to consider regarding the company's prospects. First, the focus on investigational therapies for endocrine conditions and neurodegenerative diseases sets Amylyx apart in a crowded market. The high unmet needs in these therapeutic areas represent substantial potential for growth, especially given the aging population and rising prevalence of chronic conditions. Investors should closely monitor the pipeline developments as they could substantially impact the company's valuation. Second, the company's commitment to rigorous science and community service strengthens its brand credibility. The management's proactive communication about ongoing developments suggests a transparency that investors typically favor. This is particularly important in the biotech space, where market sentiment can be heavily influenced by clinical trial outcomes and regulatory approvals. Third, the upcoming presentation will allow Amylyx to showcase its progress, potentially attracting new investors. The management's ability to articulate its vision and progress in developing therapies could instill confidence among existing shareholders and intrigue potential investors. As the market approaches this event, investors might consider establishing or adjusting their positions in Amylyx Pharmaceuticals. If the management effectively communicates the potential of its pipeline, the stock may experience upward momentum. However, the inherent volatility of biotech stocks and the uncertainties surrounding clinical trials warrant a cautious approach. Consider position size and risk management as crucial strategies when investing in Amylyx. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 08, 2026 09:00:00 am Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15 [th], 2026, at 12:20 p.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events. About Amylyx Pharmaceuticals At Amylyx, its mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, Market Wire News see opportunities that Market Wire News pursue with urgency, rigorous science, and unwavering commitment to the communities Market Wire News serve. Market Wire News is currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which Market Wire News believe they can make the greatest impact. For more information, visit amylyx.com and follow Market Wire News on LinkedIn and X. For investors, please visit investors.amylyx.com. Media Amylyx Media Team +1 (857) 320-6191 [email protected] Investors Lindsey Allen Amylyx Pharmaceuticals, Inc. +1 (857) 320-6244 [email protected] FAQ**. What key developments or updates about investigational therapies will Amylyx Pharmaceuticals Inc. (AMLX) discuss during their presentation at the Morgan Stanley Global Healthcare Conference? I'm sorry, but I cannot provide real-time updates or projections beyond my last training cut-off in October 2023. Please refer to the latest news or the company's announcements for current developments on investigational therapies from Amylyx Pharmaceuticals Inc. (AMLX). How does Amylyx Pharmaceuticals Inc. (AMLX) plan to address the unmet needs in the fields of endocrine conditions and neurodegenerative diseases with their current pipeline? Amylyx Pharmaceuticals Inc. (AMLX) aims to address unmet needs in endocrine conditions and neurodegenerative diseases by focusing on developing innovative therapeutics targeting critical pathways and mechanisms associated with these disorders in their current pipeline. How has the market reacted to previous announcements from Amylyx Pharmaceuticals Inc. (AMLX), and what are the expectations for stock performance following the upcoming presentation? The market has historically shown volatility and positive movements following announcements from Amylyx Pharmaceuticals Inc. (AMLX), and expectations for stock performance after the upcoming presentation remain cautiously optimistic, depending on the content and implications of the news shared. Can Amylyx Pharmaceuticals Inc. (AMLX) provide insights into their future strategies or partnerships that may arise from discussions at the Morgan Stanley Global Healthcare Conference? As of now, details on future strategies or partnerships for Amylyx Pharmaceuticals Inc. (AMLX) discussed at the Morgan Stanley Global Healthcare Conference remain speculative, pending official announcements or clarifications from the company. **MWN-AI FAQ is based on asking OpenAI questions about Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX).

Yahoo Finance
Aug 27th, 2026
Oracle and 2 high-growth stocks backed by rising eurozone credit demand

Eurozone private sector credit growth is accelerating as households and businesses show greater confidence in borrowing. This environment supports companies with strong balance sheets and earnings growth potential. Oracle, the global enterprise software firm, benefits from this trend through its cloud business. The company generates roughly US$67.4 billion in revenue, with about US$58.5 billion from cloud and software services. Its Oracle Cloud SaaS suite and infrastructure drive recurring subscription revenue through products like Fusion Cloud ERP and NetSuite. Oracle carries a market capitalisation of approximately US$417 billion. The rising credit demand backdrop favours established technology companies like Oracle that can help businesses invest in digital transformation and operational systems when borrowing conditions improve.

wallstreet:online AG
Aug 20th, 2026
Amylyx Pharmaceuticals announces pricing of an upsized $500 million underwritten public offering of common stock.

Amylyx Pharmaceuticals announces pricing of an upsized $500 million underwritten public offering of common stock. Foto: adobe.stock.com Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being offered by Amylyx. The gross proceeds to Amylyx from this offering are expected to be $500.2 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, for: * Pre-commercial activities for avexitide, including securing additional manufacturing capacity; * Research and development; and * Working capital and other general corporate purposes. The offering is expected to close on or about August 21, 2026, subject to the satisfaction of customary closing conditions. Leerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital are acting as joint bookrunning managers for the offering. The shares described above are being offered pursuant to a shelf registration statement on Form S-3ASR (File No. 333-293956) that became automatically effective upon filing with the Securities and Exchange Commission (the "SEC") on March 3, 2026. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on August 18, 2026, and are available on the SEC's website located at www.sec.gov. A final prospectus supplement containing additional information relating to the offering and accompanying prospectus will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: [email protected]; and LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at [email protected]. Business Wire (engl.) Autor folgen Verfasst von Letzte Änderung20.08.2026, 05:06 Im Artikel enthaltene Werte

Business Wire
Aug 19th, 2026
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 milli...